Appetite Disorder in Hemodialysis Patients and its Impact on Dietary Intake; A Cross-sectional study

By

Mohamed A.M. Elboraey1, Ibtihal M.A. Ibrahim2, Ehab Eltoraby3, Mona Tawfik4

1Internal medicine department, Dialysis Unit, Aga Central Hospital, Dakahlia, Egypt,
2Psychiatry department, Mansoura Faculty of Medicine, Mansoura university, Mansoura, Egypt,
3Internal medicine department, Rheumatology and Immunology Unit, Faculty of Medicine, Mansoura university, Mansoura, Egypt,
4Internal medicine department, Nephrology and Dialysis Unit, Faculty of Medicine, Mansoura university, Mansoura, Egypt,

Abstract

Background: Lack of appetite (anorexia) is a relatively common symptom among hemodialysis patients and contributes to the development of malnutrition; moreover, it is associated with unfavorable outcomes. This study aimed to explore the socio-demographic aspects, clinical characteristics, and appetite assessment in end-stage renal disease (ESRD) patients and study their impact on daily dietary intake. Methods: This was a cross-sectional study carried out at Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University, and Aga Hospital Dialysis Unit, Dakahlia, Egypt. The study was carried on patients with ESRD on hemodialysis. Patients who met inclusion and exclusion criteria were included in the study. Demographic and clinical characteristics were collected, and appetite was evaluated using subjective assessment of appetite then compared to dietary intake. Results: The current study included 162 hemodialysis patients whose age 48.72±12.64 years and males constituted 57.4% of them. The two main causes of ESRD in the present study were hypertension (51.9 %) and diabetic nephropathy (9.3 %). Hepatitis C virus (HCV) prevalence was found to be 36.4%. Median energy intake was 1348.5 kcal/day with (minimum-maximum) 519.78-3214.17 kcal/day, protein intake was 58.53 g/day. Significant lower values of dietary nutrient intake were observed among patients with diminished appetite category than those with normal appetite when assessed by subjective assessment of appetite. Conclusion: Diminished appetite is associated with decreased nutrient intake. Dietetic counseling is essential in HD patients to reduce rates of malnutrition.

Keywords
- End-stage renal disease
- Hemodialysis, appetite
- Malnutrition
- Nutrient

DOI : 10.21608/mjmu.2021.75294.1015
Submit Date: 2021-05-05
Accept Date: 2021-06-14
Available online:

Corresponding author: Mona Mohammed Tawfik Abdelhady, Faculty of Medicine, Mansoura University. Internal Medicine-Nephrology Unit. Mansoura University Hospitals. Street Name & Number: 60 El Gomhoureya St. City, State, Postal code, Tel: +20 50 2200720 - +20 50 2397054 - +20 50 2258545. Fax: +20 50 2397900. E-mail: mona_tawfik200099@yahoo.com
INTRODUCTION

ESRD is a permanent decline in a person’s kidney function that necessitates timely renal replacement therapy (RRT) to prevent death. It refers to those patients whose estimated glomerular filtration rate (eGFR) / 1.73 m$^2$ falls below 15 mL/minute or those needing dialysis despite GFR. \[1\]

Hemodialysis (HD) is the routine RRT in our country. The aims of HD are restoring the body’s internal environment and homeostasis. Prescribing an appropriate HD regimen that provides optimal care of the patient on chronic dialysis is adjusted according to machine-dependent variables and patient-related parameters. \[2\]

Appetite, a person’s desire to eat, is often diminished in HD patients. This abnormally diminished appetite, also known as anorexia, decreases oral intake of protein and energy, thereby leading to malnutrition and cachexia. Undoubtedly, anorexia leads to lower quality of life perception and can be a risk factor for undesirable outcomes like poor erythropoietin response and high hospitalization and mortality rates. \[3\]

Malnutrition is common in patients with ESRD. In patients receiving dialysis, the most important factor causing malnutrition is decreased nutrient intake that is owing mainly to uremia resulting from the inadequacy of dialysis. Poor dietary intake of protein and energy is commonly noticed in patients on maintenance hemodialysis. \[4\]

Decreased nutrient intake may also be caused by non-anorexic factors such as insufficient finances for buying or preparing foods, surgical or medical morbidities that impair a person’s capability of consuming, digesting, or processing the nutrients, cognitive impairment, and other mental disorders or physical disabilities. \[5\]

Assessment of appetite is generally accepted as an early warning of imminent morbidity and dietary concerns. Dietary restrictions aimed to maintain fluid, levels of serum potassium and phosphorus within normal ranges often lead to limited food options and unappetizing meals. \[6\]

To improve the outcome of dialysis, patients on dialysis need to follow a strict diet to lessen the accumulation of fluids and waste products between dialysis sessions. For patients receiving dialysis, it is important to have the proper amount intake of protein, calories, vitamins, minerals, and fluids every day. A healthy renal diet is low in sodium, potassium, and phosphorus, limited in fluids, and adequate in calories and protein. \[7\]

In this study, we aimed to explore the socio-demographic aspects, the clinical characteristics, and appetite assessment in ESRD patients receiving hemodialysis, of such patients and study their impact on daily dietary intake.

Patients and Methods

Study design and participants’ criteria:

This cross-sectional study was carried out at Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University, and Aga Hospital Dialysis Unit, Dakahlia, Egypt.

Inclusion criteria:

1- Patients older than 18 and below 65 years old.
2- On regular hemodialysis for at least six months.
3- Vitally and clinically stable.
4- Patients who were able to consume food orally and doesn't have dysphagia.
5- Patients who were able to report questionnaire (subjective assessment of appetite).

6- Patients who provided an informed consent.

**Exclusion criteria:**

1- Patients with extreme age (below 18 and above 65 years).

2- Patients who refused enrollment in the study or unable to give informed consent.

3- Patients with other diseases that associated with wasting, such as infection either, acute or chronic, and cancer.

4- Patients with recurrent illnesses or frequent history of hospital admissions in the six months before their enrollment in the study.

**Methods:**

The study was explained to all patients. Informed consent was obtained. Epidemiological, clinical, and laboratory characteristics of all patients were documented using specially prepared sheet.

- During this study, the followings were done:

1- Collection of demographic features including age, sex, gender, residence, marital status, years of education, and work.

2- Clinical characteristics were documented, especially the associated comorbidities (hypertension, diabetes mellitus, cardiovascular disease, etc.) and hepatitis C virus infection. Also, hemodialysis duration, history of renal transplantation, family history of kidney disease, and current dialysis access were reported.

3- Blood samples have been collected from each patient, and routine laboratory investigations such as serum creatinine, hemoglobin, albumin, high-sensitivity C-reactive protein (hs-CRP), urea reduction ratio (URR), calcium, phosphorus, and parathyroid hormone were done.

4- Weight in centimeters and body weight in kilograms were measured, and Body Mass Index (BMI) was calculated as weight (in kilograms) divided by the square of height (in meters). Average erythropoietin dose over three months was calculated and the mean of the three consecutive monthly doses was used in statistical analysis.

5- Dietary Assessment, patients were given a plain sheet, and they were asked to report the consumed diet over three days in a selected week. These days include a dialysis day, a day without dialysis, and a weekend day that is optional. The total dietary energy (Kcal/day) and nutrients intake {protein (g/day), fat (g/day), carbohydrate (g/day), calcium (mg/day), phosphorus (mg/day), sodium (mg/day), potassium (mg/day), water (g/day)} were calculated. The mean energy and nutrients intake over these three days were used in statistical analysis.

6- Appetite was assessed using subjective assessment of appetite tool with the following question: “During the past week, how would you rate your appetite?” that was based on a Likert scale which contained 5 response options: (1) very good, (2) good, (3) fair, (4) poor, and (5) very poor. This questionnaire was
asked to all patients on mid-week dialysis day before starting hemodialysis session. It was compared to dietary intake. We translated the available English version of the above appetite question into Arabic and was given in printed sheet for each patient separately.

**Statistical Analysis**

Data were fed to the computer and analyzed using IBM SPSS Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Qualitative data were described using number and percent. Chi-Square test for comparison of 2 or more groups. Fischer Exact test was used as correction for Chi-Square test when more than 25% of cells have count less than 5 in 2*2 tables. Quantitative data were described using median (minimum and maximum) for non-parametric data and mean, standard deviation for parametric data after testing normality using Kolmogorov-Smirnov test. The two independent groups were compared with Student t test for parametric data and Mann-Whitney U test for non-parametric data. For all the above-mentioned statistical tests done, the significance threshold is fixed at 5% level (p-value). The results were considered non-significant when the probability of error is more than 5% (p > 0.05) while significant when the probability of error is less than 5% (p ≤ 0.05).

**Results:**

In the current study, we evaluated one hundred seventy-seven ESRD patients on regular HD and only one hundred sixty-two patients were included (4 patients refused enrollment, 7 patients were on dialysis for less than six months duration, 2 patients had infections, and 3 patients were older than 65 years, and 1 patient had cancer.). The baseline demographic data are listed in table 1. The age of included sample ranged from 20 to 65, with mean 48.72 years. Sixty-nine (42.6%) of them were females, and 93 (57.4%) were males. One hundred five cases (71%) were rural residence, while 47 (29%) were from urban ones. One hundred thirty-nine cases (85.8%) were not working, 134 (82.7%) were married, with the median number of offspring was 3.

Table 2 illustrates the clinical data of the studied patients. Fifty-nine patients (36.4%) had chronic HCV. The whole sample screened negative for hepatitis B and HIV. Regarding etiology, hypertension was found in 84 patients (51.9%), diabetic nephropathy in 15 patients (9.3%), analgesic nephropathy in 14 patients (8.6%). 29 patients (17.9%) showed a positive family history of renal disease. Duration of dialysis ranged from 12-213 months, with a median of 57 months. 6 patients (3.7%) had a history of kidney transplantation. Regarding dialysis access, 155 patients (95.7%) had Arteriovenous Fistula, 4 patients (2.5%) had Arteriovenous Graft, 2 patients (1.2%) had permcath, and only one patient (0.6%) had a temporary catheter. Regarding distribution of associated co-morbidities; 88 patients (54.3%) were hypertensive, 28 patients (17.3%) were diabetic, 32 patients (19.8%) had cardiovascular disease.

The laboratory data of the studied patients are listed in table 3. Mean serum albumin was 3.99 gm/dl with standard deviation ±0.47, while mean calcium level was 8.75 mg/dl with standard deviation ±0.86, and mean phosphorus was 4.59 mg/dl with standard deviation ±1.71. On the other
hand, the mean urea reduction ratio was 68.35%, with a standard deviation of ±11.95. The mean hemoglobin level was 9.84 gm/dl with standard deviation ± 1.49, and the hs-CRP level was 6.0 mg/L with (minimum-maximum) 0.0-252 mg/L.

Additionally, the mean BMI was 27.81 Kg/m² with a standard deviation ±5.52, and the median average erythropoietin dose was 24.66 *10³ IU/month with (minimum-maximum) 0.0-78.33 *10³ IU/month. Table 4 shows dietary intake among studied cases. Median energy intake was 1348.5 kcal/day with (minimum-maximum) 519.78-3214.17 kcal/day, protein 58.53 g/day, fat 40.53 g/day, carbohydrate 187.66 g/day, calcium 381.7 mg/day, phosphorus 707.74 mg/day, sodium 2051.4 mg/day, potassium 1789.3 mg/day and water 507.21 g/day.

Table 5 illustrates the association between subjective assessment of appetite* and dietary intake of the cases included in the study. There were statistically significant lower values of dietary nutrient intake among patients with diminished appetite category than patients with a normal appetite as assessed by subjective assessment of appetite tool.

Table 6 illustrates the association between subjective assessment of appetite and co-morbidities & URR among studied cases. There was statistically significant higher frequency of hypertension among cases with diminished appetite category than those with normal appetite by subjective assessment of appetite (p=0.007). Other co-morbidities and URR showed no significant difference between the two appetite categories.

Table (1): Socio-demographic characteristics of the studied cases.

|                          | n=162 |   %
|---------------------------|-------|------
| **Age (years)**           |       |      |
| mean± SD (Range)          | 48.72±12.64 (20.0-65.0) |      |
| **Sex**                   |       |      |
| Male                       | 93    | 57.4 |
| Female                     | 69    | 42.6 |
| **Residence**             |       |      |
| Rural                      | 115   | 71.0 |
| Urban                      | 47    | 29.0 |
| **Occupation**            |       |      |
| Not working                | 139   | 85.8 |
| Working                    | 23    | 14.2 |
| **Education duration (years)** |     |      |
| median (range)            | 10.5(0.0-16.0) |      |
| **Marital status**        |       |      |
| Unmarried                  | 28    | 17.3 |
| Married                    | 134   | 82.7 |
| **Number of offspring**   |       |      |
| median (range)            | 3.0(0.0-8.0) |      |
| **Special habits**        |       |      |
| Not smoking                | 138   | 85.2 |
| Smoking                    | 24    | 14.8 |
Table (2): Medical history data of the studied cases.

|                         | n=162 | %  |
|-------------------------|-------|----|
| Hepatitis C Virus       | 59    | 36.4|
| Hepatitis B Virus       | 0     | 0.0 |
| HIV                     | 0     | 0.0 |

Etiology of Renal Failure:

| Disease                                | n     | %  |
|----------------------------------------|-------|----|
| Hypertension                           | 84    | 51.9|
| Diabetic Nephropathy                   | 15    | 9.3 |
| Analgesic Nephropathy                  | 14    | 8.6 |
| Chronic Glomerulonephritis             | 13    | 8   |
| Obstructive Nephropathy                | 13    | 8   |
| Lupus Nephritis                        | 4     | 2.5 |
| Polycystic disease of kidney           | 8     | 4.9 |
| Unknown etiology                       | 8     | 4.9 |
| Contrast-induced nephropathy           | 2     | 1.2 |
| Amyloidosis                            | 1     | 0.6 |

Family history of renal disease:

| Disease                  | n     | %  |
|--------------------------|-------|----|
| Negative                 | 133   | 82.1|
| Positive                 | 29    | 17.9|

Duration of dialysis (Months)

| Duration          | median (range) |
|-------------------|----------------|
|                   | 57.0 (12.0-213) |

History of kidney transplantation:

| Disease                  | n     | %  |
|--------------------------|-------|----|
| No                       | 156   | 96.3|
| Yes                      | 6     | 3.7 |

Current dialysis access:

| Type                  | n     | %  |
|-----------------------|-------|----|
| Arteriovenous Fistula | 155   | 95.7|
| Arteriovenous Graft   | 4     | 2.5 |
| Permcath              | 2     | 1.2 |
| Temporary catheter    | 1     | 0.6 |

Co-morbidities:

| Disease                          | n     | %  |
|----------------------------------|-------|----|
| Hypertension                     | 88    | 54.3|
| Diabetes                         | 28    | 17.3|
| Cardiovascular disease           | 32    | 19.8|
| Peripheral vascular disease      | 56    | 34.6|
| COPD                             | 6     | 3.7 |
| Stroke                           | 13    | 8.0 |
| Gastrointestinal bleeding        | 11    | 6.8 |
| Autoimmune disease               | 5     | 3.1 |

HIV= Human immunodeficiency virus, COPD= chronic obstructive pulmonary disease

Table (3): Laboratory data, BMI and EPO dose of the cases included in the study.

| Parameter                                      | n=162                        |
|------------------------------------------------|------------------------------|
| Serum albumin (g/dl)                           | 3.99±0.47                    |
| Serum creatinine (mg/dl)                       | 8.21±2.56                    |
| Calcium (mg/dl)                                | 8.75±0.86                    |
| Phosphorus (mg/dl)                             | 4.59±1.71                    |
| Parathyroid hormone (pg/ml)                    | 347.42±42.15                 |
| URR (%)                                        | 68.35±11.95                  |
| Hemoglobin (g/dl)                              | 9.84±1.49                    |
| hs-CRP (mg/l)                                  | 6.0(0.0-252)                 |
| BMI (Kg/m²)                                    | 27.8±5.52                    |
| Average EPO dose over 3 months*10³(IU/month)   | 24.66 (0.0-78.33)            |

All parameters described as mean± SD except hs-CRP and EPO dose described as median (minimum-maximum).

URR= Urea reduction ratio, hs-CRP= high sensitivity C-reactive protein, BMI= Body mass index, EPO= Erythropoietin
Table (4): Dietary intake among studied cases.

|                          |       |       |
|--------------------------|-------|-------|
|                          | n=162 |       |
| Energy (kcal/day)        | 1348.5(519.78-3214.17) |       |
| Protein (g/day)          | 58.53(18.76-184.38)    |       |
| Fat (g/day)              | 40.53(11.09-198.04)    |       |
| Carbohydrates (g/day)    | 187.66(72.15-534.9)    |       |
| Calcium (mg/day)         | 381.7(60.62-965.88)    |       |
| Phosphorus (mg/day)      | 707.74(102.32-3097.3)  |       |
| Sodium (mg/day)          | 2051.4(289.87-8817.6)  |       |
| Potassium (mg/day)       | 1789.3(467.42-4610.1)  |       |
| Water (g/day)            | 507.21(168.21-1445.3)  |       |

All parameters described as median (min-max)

Table (5): Association between subjective assessment of appetite* and dietary intake of the cases included in the study.

| Subjective assessment of appetite | Energy (kcal/day) | Protein (g/day) | Fat (g/day) | Carbohydrate (g/day) | Calcium (mg/day) | Phosphorus (mg/day) | Sodium (mg/day) | Potassium (mg/day) | Water (g/day) |
|----------------------------------|------------------|----------------|------------|----------------------|-----------------|--------------------|-----------------|-------------------|--------------|
| Normal                           | 1580.8±473.5     | 68.09±20.42    | 46.16(14.79-198.04) | 224.41±80.73       | 424.57(60.62-965.88) | 799.25 (307.7-3097.3) | 2339.4(289.87-8817.6) | 2099.8±687.64     | 639.08±204.0  |
| Diminished                       | 1143.3±335.52    | 49.91±16.52    | 34.57(11.09-169.02) | 160.07±50.59       | 318.27 (91.72-877.67) | 562.97(102.32-1332.7) | 1650.92(507.4-3695.27) | 1570.0±552.30     | 445.13±138.06 |

*statistically significant  t: Student t test  p: probability  Z: Mann Whitney U test  FET: Fischer exact test

Table 6: Association between subjective assessment of appetite and co-morbidities & URR among studied cases.

| Subjective assessment of appetite | Hypertension | Diabetes | Cardiovascular disease | Peripheral vascular disease | Chronic obstructive pulmonary disease | Stroke | Gastrointestinal bleeding | Autoimmune disease | URR (%) |
|----------------------------------|--------------|----------|------------------------|-----------------------------|--------------------------------------|--------|---------------------------|--------------------|---------|
| Normal                           | 41(45.1)     | 14(15.4) | 18(19.8)               | 27(29.7)                    | 5(5.5)                               | 5(5.5) | 9(9.9)                    | 2(2.2)             | 69.21±11.85|
| Diminished                       | 47(66.2)     | 14(19.7) | 14(19.7)               | 29(40.8)                    | 1(1.4)                               | 8(11.3) | 2(2.8)                    | 3(4.2)             | 67.25±12.07|

URR was described as mean± SD  □:=Chi-Square test  FET: Fisher exact test  t: student t test  p: probability  *statistically significant
Discussion

The current study included 162 patients with ESRD on dialysis, 57.4 of them were males and the mean age of the patients was 48.72 years. The high percentage of male patients in this study was in concordance with Hecking et al., who reported that more men were on hemodialysis than women (59% versus 41% overall). [11] Moreover, Nagata et al. reported that ESRD was more prevalent in males, particularly after 50 years. [12] Furthermore, some female patients refused enrollment in the study. On the other hand, our result was matched with Afifi et al. who reported that the mean age of HD patients in Egypt increased from 45.6 years in 1996 to 49.8 years in 2008 [13] and the 9th Annual Report of The Egyptian Renal Registry, which showed that the mean age of HD patients was about 49.8 ± 19 years and 55.2% of them were males. [14] Also, this was in agreement with the study performed by Yu et al., who reported a rise in the prevalence of CRF with aging. [15]

In the present study, hypertension was the main cause of ESRD (51.9%), followed by diabetic nephropathy (DN) (9.3%) and this came in agreement with Ghazaly et al. who reported that in Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University, Dakahlya, hypertension was the main cause of ESRD (41%), followed by diabetes (25%). [16] Also, a similar result is reported in a number of governorates in Egypt. El-Zorkany reported that in Menoufia, the leading cause of ESRD was hypertension (33.4%), followed by DN (9.2%). [17] Ahmed et al. reported that in Beheira the major cause of ESRD was hypertension (27.8%), followed by DN (20.1%). [18] El Minshawy reported that in Cairo hypertension was the major cause of ESRD with 29.7%, followed by DN 12.5%; in Canal governorates hypertension was the leading cause of ESRD with 27.3% followed by DN (10.7%) and in El-Minia governorate the main cause was also hypertension (20%), followed by DN (8%). [19] This high prevalent etiology of hypertension in this current study may be attributed to lower rates of awareness, lack of early screening through hypertension-screening programs and negligence of hypertension treatment, especially in areas of low socioeconomic status.

The findings of the current study are also compatible with results from other Arab countries. Banaga et al. reported that in Sudanese, the most common cause of ESRD was hypertension (34.6%), followed by chronic glomerulonephritis (17.6%), then DN (12.8%). [20] Additionally, Moukeh et al. who reported that in Syrian, hypertension represented the main cause of ESRD (21.5%), followed by chronic glomerulonephritis (20.5%), then DN (19.5%) and counts the third cause. [21]

In contrast to the current result, Saran et al. reported that in USA, the main cause of ESRD was DM. [22] Also, Hassanien et al. reported that in the Gulf Cooperation Council countries, the leading cause of ESRD was DN (17). [23]

There is an increased risk for catching HCV infection among HD patients. [24] In our study, the prevalence of HCV was found to be 36.4%. Ghazaly's et al. study carried out in the nephrology and dialysis unit in Mansoura University Hospital, Dakahlya, Egypt, showed that 26 of 100 ESRD patients (26%) were tested positive for HCV Antibody. [25] Elmowafy et al. reported that in the Urology and Nephrology Center, Mansoura
University, Dakahlya, 46 of 96 HD patients (47.9%) had HCV Antibody. Also, Anber et al. reported that in Mansoura University Hospital, Dakahlya, 48 of 93 chronic HD patients (51.8%) had HCV Antibody. Kerollo et al. reported that in Assiut governorate the prevalence of HCV among HD patients was 34.8%. El-Zorkany reported that in Menoufia the prevalence of HCV in the ESRD patients was found to be 36.8%. The high prevalence of HCV in this current study may be attributed to lack of implementing standard precautions for infection control in dialysis centers or transmission of infection outside dialysis centers e.g., at barbershop during hair cutting and shaving, especially in low-income areas. In Egypt, the prevalence of HCV in HD patients in 2015 survey was estimated to be 50.7%. In the current study, median daily energy intake was 1348.5 kcal/day, protein 58.53 g/day, carbohydrate 187.66 g/day. Cupisti et al. reported that mean dietary energy intake was 1900 Kcal/day, mean protein was 70 g/day, mean carbohydrate was 238 g/day.

The recommended dietary energy intake for HD patients is 35 Kcal/kg/day, and 30-35 Kcal/kg/day if below 60 and 60 years or older, respectively; dietary protein intake 1.2 g/kg/d for clinically stable patients (at least 50% should be of high biological value); total fat 25-35% of total energy intake; potassium 2000-2750 mg/day; sodium 750-2000 mg/day; phosphorus 800-1000 mg/day; calcium <1000 mg/day; water 750-1500 ml/day.

We observed that there were significant lower values for dietary energy and protein intakes among patients with diminished appetite than patients with normal appetite. Low dietary intake of energy and protein in those patients with diminished appetite may be due to inadequate dialysis as some patients were not compliant to receive the full time of dialysis session. Moreover, other factors might contribute such as psychological disorders, and working status as 85.8 of the studied patients were not working and this participate in poverty and low socio-economic status.

Burrowes et al. reported significant lower values for dietary energy and protein intakes among patients with fair, poor/very poor appetite than patients with very good, good appetite. Also, Sahathevan et al. reported that patients with the poorer appetite ratings (fair, poor) had significantly lower dietary energy and protein intakes. Hajira et al. observed that the dietary intake of energy and protein are often low due to uremic anorexia, underlying disease, and psychological factors.

We observed that frequency of hypertension comorbidity was statistically significant among patients with diminished appetite category than patients with normal appetite by subjective assessment of appetite. The reason for this finding is not clear. On the contrary, this disagreed with Sahathevan et al. and Kalanter-Zadeh et al. who observed that there was no significant association between underlying hypertension comorbidity and subjective assessment of appetite. Also, we observed that frequency of diabetes and cardiovascular disease comorbidities showed no statistically significant difference across the two appetite categories (normal & diminished), and this agreed with
Sahathevan et al. and Kalanter-Zadeh et al. who observed no significant association between diabetes and cardiovascular disease among the two appetite categories [36,37].

We observed that URR was not statistically differ across the two appetite categories (normal, diminished), this may be attributed to the fact the subjective assessment of appetite is limited-time frame assessment tool (the past week only) [38,39] and this agreed with Sahathevan et al. and Kalanter-Zadeh et al. who observed no statistically difference between Kt/V showed no statistically difference across appetite categories. (very good, good, fair, poor, very poor) [40,41]

References:
1. Inker, L. A., Astor, B. C., Fox, C. H., et al. (2014). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis, 63(5), 713-735.
2. Ikizler, T. A., & Schulman, G. (2005). Hemodialysis: techniques and prescription. Am J kidney Dis, 46(5), 976-981.
3. Oner-Iyidogan, Y., Gurdol, F., Kocak, H., et al. (2011). Appetite-regulating hormones in chronic kidney disease patients. J Ren Nutr. 21(4), 316-321.
4. Kang, S. S., Chang, J. W., & Park, Y. (2017). Nutritional status predicts 10-year mortality in patients with end-stage renal disease on hemodialysis. Nutrients, 9(4), 399.
5. Obi, Y., Qader, H., Kovesdy, C. P., et al. (2015). Latest consensus and update on protein energy-wasting in chronic kidney disease. Current opinion in clinical nutrition and metabolic care. 18(3), 254.
6. Palmer, S. C., Hanson, C. S., Craig, J. C., et al. (2015). Dietary and fluid restrictions in CKD: a thematic synthesis of patient views from qualitative studies. Am J Kidney Dis. 65(4), 559-573.
7. Gamal, D., Mohammed, A. E. A., Saleh Shahin, E., et al. (2016). Assessment of Nutritional Needs for Patients Undergoing Hemodialysis. Port Said sci. nurs., 3(2), 59-79.
8. Fouque, D., Vennegoor, M., Ter Wee, P., et al. (2007). EBPG guideline on nutrition. Nephrol Dial Transplant. 22(suppl 2), ii45-ii87.
9. Kalantar-Zadeh, K., Block, G., Mcallister, C. J., et al. (2004). Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. The Am. J. Clin. Nutr. 80(2), 299-307.
10. Burrowes, J. D., Larive, B., Chertow, G. M., et al. (2005). Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant. 20(12), 2765-2774.
11. Hecking, M., Bieber, B. A., Ethier, J., et al. (2014). Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med. 11(10), e1001750.
12. Nagata, M., Ninomiya, T., Doi, Y., et al. (2010). Trends in the prevalence of chronic kidney disease and its risk factors in a
general Japanese population: the Hisayama Study. Nephrol Dial Transplant. 25(8), 2557-2564.

13. Afifi, A. (2008). The Egyptian Renal Registry. The 9th annual report for the year. 256-261.

14. Afifi, A. & Karim, M. A. (1999). Renal replacement therapy in Egypt: first annual report of the Egyptian Society of Nephrology, 1996. EMHJ-Eastern Mediterranean Health Journal, 5 (5), 1023-1029, 1999.

15. Yu, M., Ryu, D.-R., Kim, S.-J., et al. (2010). Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey. Nephrol Dial Transplant. 25(2), 469-477.

16. Ghazaly, E. A., El-Saeed, A. M., Abdelsalam, M., et al. (2020). Potential protective effect of leptin and uncoupling protein-2 genes polymorphism in Egyptian patients with chronic kidney disease. Int Urol Nephrol, 52(11), 2153-2160.

17. El-Zorkany, K. M. (2017). Maintenance hemodialysis in Menoufia governorate, Egypt: Is there any progress? J Egypt Soc Nephrol Transplant. 17(2), 58.

18. Ahmed, H. A., Zahran, A. M. & Issawi, R. A. (2020). Prevalence and etiology of end-stage renal disease patients on maintenance hemodialysis. Menoufia Med J. 33(3), 766.

19. El Minshawy, O. (2011). End-stage renal disease in the El-Minia Governorate, upper Egypt: an epidemiological study. Saudi J Kidney Dis Transpl. 22(5), 1048.

20. Banaga, A. S., Mohammed, E. B., Siddig, R. M., et al. (2015). Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan. BMC research notes. 8(1), 1-7.

21. Moukeh, G., Yacoub, R., Fahdi, F., et al. (2009). Epidemiology of hemodialysis patients in Aleppo city. Saudi J Kidney Dis Transpl. 20(1), 140.

22. Saran, R., Robinson, B., Abbott, K. C., et al. (2017). US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 69(3), A7-A8.

23. Hassani, A. A., Al-Shaikh, F., Vamos, E. P., et al. (2012). Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review. JRSM short reports. 3(6), 1-21.

24. Pol, S., Vallet-Pichard, A., Fontaine, H., et al. (2002). HCV infection and hemodialysis. Seminars in nephrology. Elsevier, 22(4), 331-339.

25. Ghazaly, E. A., El-Saeed, A. M., Abdelsalam, M., et al. (2020). Potential protective effect of leptin and uncoupling protein-2 genes polymorphism in Egyptian patients with chronic kidney disease. Int Urol. Nephrol, 51(9), 1639-1647.

26. Elmowafy, A. Y., El Maghrabi, H. M., Eldahshan, K. F., et al. (2019). Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. Int. urol. nephrol, 51(9), 1639-1647.

27. Anber, N., Abd El Salam, M., Abd El Wahab, A. M., et al. (2016). Prevalence of Occult Hepatitis C in Chronic Hemodialysis
Patients in Mansoura University Hospital, Egypt. Int J Adv Pharm, Biol Chem, 5, 73.

28. Kerollos, K. M. N., El-Ameen, H. A., Abd El Wahed, L., et al. (2020). Prevalence and seroconversion of hepatitis C among hemodialysis patients in Assiut governorate, Egypt. The Egyptian Journal of Internal Medicine. 32(1), 1-6.

29. El-Zorkany, K. M. (2017). Maintenance hemodialysis in Menoufia governorate, Egypt: Is there any progress? J Egypt Soc Nephrol Transplant. 17(2), 58.

30. El-Zanaty, F., & Way, A. (2015). Egypt health issue survey. Ministry of Health and Population, Cairo, Egypt.

31. Cupisti, A., D’Alessandro, C., Valeri, A., et al. (2010). Food intake and nutritional status in stable hemodialysis patients. Renal failure, 32(1), 47-54.

32. Therrien, M., Byham-Gray, L., & Beto, J. (2015). A review of dietary intake studies in maintenance dialysis patients. J. Ren. Nutr. 25(4), 329-338.

33. Burrowes, J. D., Larive, B., Chertow, G. M., et al. (2005). Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant. 20(12), 2765-2774.

34. Sahathevan, S., Se, C. H., Ng, S. H., et al. (2015). Assessing protein energy wasting in a Malaysian haemodialysis population using self-reported appetite rating: a cross-sectional study. BMC nephrology. 16(1), 1-12.

35. Hajira, B., Samiullah, M. and Chawla, R. K. (2013). Nutritional status assessment of hemodialysis patients at rehman medical institute peshawar. ARPN J. Agri. Biol. Sci., 8(4), 329-336.

36. Sahathevan, S., Se, C. H., Ng, S. H., et al. (2015). Assessing protein energy wasting in a Malaysian haemodialysis population using self-reported appetite rating: a cross-sectional study. BMC nephrology. 16(1), 1-12.

37. Kalantar-Zadeh, K., Block, G., Mcallister, C. J., et al. (2004). Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. The Am. J. Clin. Nutr. 80(2), 299-307.

38. Burrowes, J. D., Larive, B., Chertow, G. M., et al. (2005). Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant. 20(12), 2765-2774.

39. Kalantar-Zadeh, K., Block, G., Mcallister, C. J., et al. (2004). Appetite and inflammation, nutrition, anemia, and